CFP SYMPTEMIST (BioCreative VIII @ AMIA 2023): Named entity recognition & linking of symptoms (incl. multilingual dataset)
Martin Krallinger via Corpora <[email protected]> Fri, 18 Aug 2023 17:29:52 +0200
| Newsgroups | gmane.science.linguistics.corpora,gmane.org.w3c.semantic-web |
|---|---|
| Message-ID | <CAMx+MKGnxmNEXEmZT0j74Tp=Lg7=UGGv3hCDSdb6F58cDUKRZA@mail.gmail.com> |
--===============6986709136075456075== Content-Type: multipart/alternative; boundary="000000000000e22a4806033433d8" --000000000000e22a4806033433d8 Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: quoted-printable (Apologies for cross-posting) CFP: SYMPTEMIST Shared Task (BioCreative VIII run with AMIA 2023) Named entity recognition and linking of symptoms, signs & findings (incl. multilingual dataset) https://temu.bsc.es/SYMPTEMIST/ <https://temu.bsc.es/distemist/> The SYMPTEMIST track focuses on the automatic detection of mentions of clinical symptoms (NER) and mapping to concept identifiers in clinical case reports in Spanish (entity linking). Also a multilingual version of the dataset will be released including versions in English, French, Italian, Dutch, Portuguese, Romanian and Swedish. Key information: - Web: https://temu.bsc.es/symptemist - Data: <https://doi.org/10.5281/zenodo.6408476> https://zenodo.org/record/8223654 - Annotation guidelines: https://zenodo.org/record/8246440 - BioCreative web: https://biocreative.bioinformatics.udel.edu - Registration form (Track 2- SYMPTEMIST): <https://temu.bsc.es/distemist/registration/> https://docs.google.com/forms/d/e/1FAIpQLScoSNulOoxRju3c8v9Q-CSv-w5jJcXu= 93G7A7v343AWfonpPw/viewform Motivation Systems able to detect and normalize clinical symptom mentions from medical texts are crucial for almost any healthcare data mining, AI, medical analytics or predictive application. As opposed to other clinical information types, such as diagnoses (diseases/procedures), lab test results or even medications, clinical symptoms can only be recovered directly from written clinical narratives. Due to the high complexity, variability and difficulty in generating annotated corpora for clinical symptoms, only few large manually annotated data collections have been constructed so far, with certain underlying limitations in terms of a) entity linking / normalization of the symptom mentions to controlled vocabularies and b) a lack of attempts to promote the development of multilingual solutions and b) provide detailed annotation criteria and guidelines. To address these issues, we have posed the SYMPTEMIST track at the upcoming BioCreative VIII initiative, which will be run in the context of the prestigious AMIA 2023 conference, which received over 1400 submissions this year. Automatic detection of symptoms mentions are key for a range of clinical use cases and real world applications like: - Predictive modeling of diseases - Differential diagnosis of complex diseases - Rare disease characterization & analysis - Selection of appropriate treatment & therapy - Study of disease-symptom associations - Early detection of disease outbreaks & epidemiological surveillance - Extraction of phenotypes - Drug repurposing & off label indications The SYMPTEMIST organizers will also release multilingual resources to foster the development of multilingual tools and generate systems not only for Spanish but also for content in English and Romance languages (French, Portuguese, Italian, Romanian and Catalan) as well as versions in Dutch, Swedish and Czech. Inspired by previous initiatives (e.g. n2c2, CLEF or TREC) and shared tasks (CANTEMIST, PharmaCoNER, or CodiEsp), we are launching the SYMPTEMIST shared task as part of the BioCreative 2023 evaluation initiative, with the following three sub-tracks: - SYMPTEMIST-entities: automatic detection of mentions of symptoms. - SYMPTEMIST-linking: finding mentions of symptoms and normalizing them to their Snomed-CT concept identifiers. - SYMPTEMIST-multilingual: automatic detection of mentions of symptoms in versions of the corpus generated in English, French, Italian, Portuguese= , Romanian, Catalan, Dutch, Swedish and Czech. Tentative schedule - Annotation Guidelines: August 8th 2023 - Train Set Subtask 1 (NER): August 8th, 2023 - Train Set Subtask 2 (Linking): September 10th 2023 - Train Set Subtask 3 (Multilingual): September 10th 2023 - SympTEMIST Test Set: September 30th 2023 - Participants Test Predictions Deadline: October 5th 2023 - Participants Evaluation Results Release. October 10th 2023 - Submission of Participant Papers Deadline: October 22nd 2023 - Notification of Acceptance Participant Papers: October 30 2023 - Submission of Camera-ready Participant Papers Deadline. November 1st 202= 3 - BioCreative VIII workshop @ AMIA 2023: November 11-15, 2023, In New Orleans, LA. BioCreative proceedings and AMIA workshop Teams participating in SYMPTEMIST will be invited to contribute a systems description paper for the BioCreative 2023 Working Notes proceedings and a flash presentation of their approach at the BioCreative 2023 session. The BioCreative VIII workshop will run with AMIA 2023, November 11-15, 2023, In New Orleans, LA. See: https://amia.org/education-events/amia-2023-annual-symposium Workshop Proceedings and Special Issue: The BioCreative VIII Proceedings will host all the submissions from participating teams, and it will be freely available by the time of the workshop. In addition, we are happy to announce that the journal Database will host the BioCreative VIII special issue for work that has passed their peer-review process. Invitation to submit will be sent after the workshop. All BioCreative VIII tracks Track 1: BioRED (Biomedical Relation Extraction Dataset) *Track 2: SYMPTEMIST (Symptom TExt Mining Shared Task) Track 3: Genetic Phenotype Extraction and Normalization from Dysmorphology Physical Examination Entries Track 4: Clinical Annotation Tool Track Main Organizers - Martin Krallinger, Barcelona Supercomputing Center, Spain - Eul=C3=A0lia Farr=C3=A9-Maduell, Barcelona Supercomputing Center, Spain - Luis Gasc=C3=B3, Barcelona Supercomputing Center, Spain - Salvador Lima, Barcelona Supercomputing Center, Spain - Jan Rodriguez, Barcelona Supercomputing Center, Spain =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D Martin Krallinger, Dr. Head of NLP for Biomedical Information Analysis Unit Barcelona Supercomputing Center (BSC-CNS) https://www.linkedin.com/in/martin-krallinger-85495920/ =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D --000000000000e22a4806033433d8 Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: quoted-printable <div dir=3D"ltr"><span id=3D"gmail-docs-internal-guid-7fba9f1a-7fff-bd34-38= 5e-916fca66a844"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;ma= rgin-bottom:0pt"><span style=3D"font-size:11pt;font-family:Arial,sans-serif= ;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;= font-variant-east-asian:normal;font-variant-alternates:normal;vertical-alig= n:baseline">(Apologies for cross-posting)</span></p><br><p dir=3D"ltr" styl= e=3D"line-height:1.44;text-align:center;margin-top:10pt;margin-bottom:10pt"= ><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0= ,0);background-color:transparent;font-weight:700;font-variant-numeric:norma= l;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-al= ign:baseline">CFP: SYMPTEMIST Shared Task (BioCreative VIII run with AMIA 2= 023)=C2=A0</span></p><p dir=3D"ltr" style=3D"line-height:1.44;text-align:ce= nter;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-size:10pt;font-f= amily:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font= -weight:700;font-variant-numeric:normal;font-variant-east-asian:normal;font= -variant-alternates:normal;vertical-align:baseline">Named entity recognitio= n and linking of symptoms, signs & findings (incl. multilingual dataset= )</span></p><p dir=3D"ltr" style=3D"line-height:1.44;text-align:center;marg= in-top:0pt;margin-bottom:0pt;padding:0pt 0pt 10pt"><a href=3D"https://temu.= bsc.es/distemist/" style=3D"text-decoration-line:none"><span style=3D"font-= size:10pt;font-family:Calibri,sans-serif;background-color:transparent;font-= variant-numeric:normal;font-variant-east-asian:normal;font-variant-alternat= es:normal;text-decoration-line:underline;vertical-align:baseline">https://t= emu.bsc.es/SYMPTEMIST/</span></a></p><p dir=3D"ltr" style=3D"line-height:1.= 44;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-= size:11pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background-color:tr= ansparent;font-variant-numeric:normal;font-variant-east-asian:normal;font-v= ariant-alternates:normal;vertical-align:baseline">=C2=A0</span></p><p dir= =3D"ltr" style=3D"line-height:1.44;text-align:justify;margin-top:0pt;margin= -bottom:0pt;padding:10pt 0pt"><span style=3D"font-size:10pt;font-family:Cal= ibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-= numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma= l;vertical-align:baseline">The SYMPTEMIST track focuses on the automatic de= tection of mentions of clinical symptoms (NER) and mapping to concept ident= ifiers in clinical case reports in Spanish (entity linking). Also a multili= ngual version of the dataset will be released including versions in English= , French, Italian, Dutch, Portuguese, Romanian and Swedish.</span></p><p di= r=3D"ltr" style=3D"line-height:1.44;margin-top:0pt;margin-bottom:0pt"><span= style=3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);ba= ckground-color:transparent;font-weight:700;font-variant-numeric:normal;font= -variant-east-asian:normal;font-variant-alternates:normal;vertical-align:ba= seline">Key information:</span></p><ul style=3D"margin-top:0px;margin-botto= m:0px"><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-fa= mily:Arial,sans-serif;color:rgb(0,0,0);background-color:transparent;font-va= riant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates= :normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p dir=3D= "ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"p= resentation"><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;b= ackground-color:transparent;font-weight:700;font-variant-numeric:normal;fon= t-variant-east-asian:normal;font-variant-alternates:normal;vertical-align:b= aseline">Web</span><span style=3D"font-size:10pt;font-family:Calibri,sans-s= erif;background-color:transparent;font-variant-numeric:normal;font-variant-= east-asian:normal;font-variant-alternates:normal;vertical-align:baseline">:= <a href=3D"https://temu.bsc.es/symptemist">https://temu.bsc.es/symptemist<= /a></span></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:= 10pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background-color:transpa= rent;font-variant-numeric:normal;font-variant-east-asian:normal;font-varian= t-alternates:normal;vertical-align:baseline;white-space:pre;margin-left:11p= t"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0p= t" role=3D"presentation"><span style=3D"font-size:10pt;font-family:Calibri,= sans-serif;background-color:transparent;font-weight:700;font-variant-numeri= c:normal;font-variant-east-asian:normal;font-variant-alternates:normal;vert= ical-align:baseline">Data</span><span style=3D"font-size:10pt;font-family:C= alibri,sans-serif;background-color:transparent;font-variant-numeric:normal;= font-variant-east-asian:normal;font-variant-alternates:normal;vertical-alig= n:baseline">:</span><a href=3D"https://doi.org/10.5281/zenodo.6408476" styl= e=3D"text-decoration-line:none"><span style=3D"font-size:10pt;font-family:C= alibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-varian= t-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:nor= mal;vertical-align:baseline"> </span></a><span style=3D"font-size:10pt;font= -family:Calibri,sans-serif;color:rgb(17,85,204);background-color:transparen= t;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-a= lternates:normal;text-decoration-line:underline;vertical-align:baseline"><a= href=3D"https://zenodo.org/record/8223654">https://zenodo.org/record/82236= 54</a></span></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-si= ze:10pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background-color:tran= sparent;font-variant-numeric:normal;font-variant-east-asian:normal;font-var= iant-alternates:normal;vertical-align:baseline;white-space:pre;margin-left:= 11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom= :0pt" role=3D"presentation"><span style=3D"font-size:10pt;font-family:Calib= ri,sans-serif;background-color:transparent;font-weight:700;font-variant-num= eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;v= ertical-align:baseline">Annotation guidelines</span><span style=3D"font-siz= e:10pt;font-family:Calibri,sans-serif;background-color:transparent;font-var= iant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:= normal;vertical-align:baseline">: <a href=3D"https://zenodo.org/record/8246= 440">https://zenodo.org/record/8246440</a></span></p></li><li dir=3D"ltr" s= tyle=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;= color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;f= ont-variant-east-asian:normal;font-variant-alternates:normal;vertical-align= :baseline;white-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-he= ight:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span sty= le=3D"font-size:10pt;background-color:transparent;font-weight:700;font-vari= ant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:n= ormal;vertical-align:baseline">BioCreative web</span><span style=3D"font-si= ze:10pt;background-color:transparent;font-variant-numeric:normal;font-varia= nt-east-asian:normal;font-variant-alternates:normal;vertical-align:baseline= ">: </span><a href=3D"https://biocreative.bioinformatics.udel.edu" style=3D= "text-decoration-line:none"><span style=3D"font-size:10pt;background-color:= transparent;font-variant-numeric:normal;font-variant-east-asian:normal;font= -variant-alternates:normal;text-decoration-line:underline;vertical-align:ba= seline">https://biocreative.bioinformatics.udel.edu</span></a></p></li><li = dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-family:Calibr= i,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-num= eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;v= ertical-align:baseline;white-space:pre;margin-left:11pt"><p dir=3D"ltr" sty= le=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentati= on"><span style=3D"font-size:10pt;background-color:transparent;font-weight:= 700;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant= -alternates:normal;vertical-align:baseline">Registration form (</span><span= style=3D"font-size:10pt;color:rgb(32,33,36);font-weight:700;font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;vertical-align:baseline">Track 2- SYMPTEMIST</span><span style=3D"font-siz= e:10pt;background-color:transparent;font-weight:700;font-variant-numeric:no= rmal;font-variant-east-asian:normal;font-variant-alternates:normal;vertical= -align:baseline">)</span><span style=3D"font-size:10pt;background-color:tra= nsparent;font-variant-numeric:normal;font-variant-east-asian:normal;font-va= riant-alternates:normal;vertical-align:baseline">:</span><a href=3D"https:/= /temu.bsc.es/distemist/registration/" style=3D"text-decoration-line:none"><= span style=3D"font-size:10pt;color:rgb(0,0,0);background-color:transparent;= font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-alt= ernates:normal;vertical-align:baseline"> </span></a><a href=3D"https://docs= .google.com/forms/d/e/1FAIpQLScoSNulOoxRju3c8v9Q-CSv-w5jJcXu93G7A7v343AWfon= pPw/viewform" style=3D"text-decoration-line:none"><span style=3D"font-size:= 10pt;background-color:transparent;font-variant-numeric:normal;font-variant-= east-asian:normal;font-variant-alternates:normal;text-decoration-line:under= line;vertical-align:baseline">https://docs.google.com/forms/d/e/1FAIpQLScoS= NulOoxRju3c8v9Q-CSv-w5jJcXu93G7A7v343AWfonpPw/viewform</span></a></p></li><= /ul><p dir=3D"ltr" style=3D"line-height:1.44;text-align:justify;margin-top:= 10pt;margin-bottom:0pt;padding:0pt 0pt 10pt"><span style=3D"font-size:10pt;= font-family:Calibri,sans-serif;color:rgb(17,85,204);background-color:transp= arent;font-variant-numeric:normal;font-variant-east-asian:normal;font-varia= nt-alternates:normal;text-decoration-line:underline;vertical-align:baseline= "><br></span><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;c= olor:rgb(0,0,0);background-color:transparent;font-weight:700;font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;vertical-align:baseline">Motivation</span><span style=3D"font-size:10pt;fo= nt-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;= font-weight:700;font-variant-numeric:normal;font-variant-east-asian:normal;= font-variant-alternates:normal;vertical-align:baseline"><br></span><span st= yle=3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);backg= round-color:transparent;font-variant-numeric:normal;font-variant-east-asian= :normal;font-variant-alternates:normal;vertical-align:baseline">Systems abl= e to detect and normalize clinical symptom mentions from medical texts are = crucial for almost any healthcare data mining, AI, medical analytics or pre= dictive application. As opposed to other clinical information types, such a= s diagnoses (diseases/procedures), lab test results or even medications, cl= inical symptoms can only be recovered directly from written clinical narrat= ives. Due to the high complexity, variability and difficulty in generating = annotated corpora for clinical symptoms, only few large manually annotated = data collections have been constructed so far, with certain underlying limi= tations in terms of a) entity linking / normalization of the symptom mentio= ns to controlled vocabularies and b) a lack of attempts to promote the deve= lopment of multilingual solutions and b) provide detailed annotation criter= ia and guidelines. To address these issues, we have posed the SYMPTEMIST tr= ack at the upcoming BioCreative VIII initiative, which will be run in the c= ontext of the prestigious AMIA 2023 conference, which received over 1400 su= bmissions this year.</span></p><p dir=3D"ltr" style=3D"line-height:1.44;tex= t-align:justify;margin-top:0pt;margin-bottom:10pt"><span style=3D"font-size= :10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:tran= sparent;font-variant-numeric:normal;font-variant-east-asian:normal;font-var= iant-alternates:normal;vertical-align:baseline">Automatic detection of symp= toms mentions are key for a range of clinical use cases and real world appl= ications like:</span></p><ul style=3D"margin-top:0px;margin-bottom:0px"><li= dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-family:Calib= ri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-nu= meric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;= vertical-align:baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-heigh= t:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style= =3D"font-size:10pt;background-color:transparent;font-variant-numeric:normal= ;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-ali= gn:baseline">Predictive modeling of diseases</span></p></li><li dir=3D"ltr"= style=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-seri= f;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal= ;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-ali= gn:baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.38;margi= n-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size= :10pt;background-color:transparent;font-variant-numeric:normal;font-variant= -east-asian:normal;font-variant-alternates:normal;vertical-align:baseline">= Differential diagnosis of complex diseases</span></p></li><li dir=3D"ltr" s= tyle=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;= color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;f= ont-variant-east-asian:normal;font-variant-alternates:normal;vertical-align= :baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.38;margin-= top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:1= 0pt;background-color:transparent;font-variant-numeric:normal;font-variant-e= ast-asian:normal;font-variant-alternates:normal;vertical-align:baseline">Ra= re disease characterization & analysis</span></p></li><li dir=3D"ltr" s= tyle=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;= color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;f= ont-variant-east-asian:normal;font-variant-alternates:normal;vertical-align= :baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.38;margin-= top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:1= 0pt;background-color:transparent;font-variant-numeric:normal;font-variant-e= ast-asian:normal;font-variant-alternates:normal;vertical-align:baseline">Se= lection of appropriate treatment & therapy</span></p></li><li dir=3D"lt= r" style=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-se= rif;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:norm= al;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-a= lign:baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.38;mar= gin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-si= ze:10pt;background-color:transparent;font-variant-numeric:normal;font-varia= nt-east-asian:normal;font-variant-alternates:normal;vertical-align:baseline= ">Study of=C2=A0 disease-symptom associations</span></p></li><li dir=3D"ltr= " style=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-ser= if;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:norma= l;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-al= ign:baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.38;marg= in-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-siz= e:10pt;background-color:transparent;font-variant-numeric:normal;font-varian= t-east-asian:normal;font-variant-alternates:normal;vertical-align:baseline"= >Early detection of disease outbreaks & epidemiological surveillance</s= pan></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;f= ont-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent= ;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-al= ternates:normal;vertical-align:baseline;white-space:pre"><p dir=3D"ltr" sty= le=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentati= on"><span style=3D"font-size:10pt;background-color:transparent;font-variant= -numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norm= al;vertical-align:baseline">Extraction of phenotypes</span></p></li><li dir= =3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,s= ans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-numeri= c:normal;font-variant-east-asian:normal;font-variant-alternates:normal;vert= ical-align:baseline;white-space:pre"><p dir=3D"ltr" style=3D"line-height:1.= 38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"f= ont-size:10pt;background-color:transparent;font-variant-numeric:normal;font= -variant-east-asian:normal;font-variant-alternates:normal;vertical-align:ba= seline">Drug repurposing & off label indications=C2=A0</span></p></li><= /ul><br><p dir=3D"ltr" style=3D"line-height:1.44;margin-top:0pt;margin-bott= om:12pt"><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;color= :rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;font-v= ariant-east-asian:normal;font-variant-alternates:normal;vertical-align:base= line">The SYMPTEMIST organizers will also release multilingual resources to= foster the development of multilingual tools and generate systems not only= for Spanish but also for content in English and Romance languages (French,= Portuguese, Italian, Romanian and Catalan) as well as versions in Dutch, S= wedish and Czech.</span></p><p dir=3D"ltr" style=3D"line-height:1.44;margin= -top:0pt;margin-bottom:12pt"><span style=3D"font-size:10pt;font-family:Cali= bri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;vertical-align:baseline">Inspired by previous initiatives (e.g. n2c2, CLEF= or TREC) and shared tasks (CANTEMIST, PharmaCoNER, or CodiEsp), we are lau= nching the SYMPTEMIST shared task as part of the BioCreative 2023 evaluatio= n initiative, with the following three sub-tracks:</span></p><ul style=3D"m= argin-top:0px;margin-bottom:0px"><li dir=3D"ltr" style=3D"list-style-type:d= isc;font-size:10pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background= -color:transparent;font-variant-numeric:normal;font-variant-east-asian:norm= al;font-variant-alternates:normal;vertical-align:baseline;white-space:pre;m= argin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;ma= rgin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:10pt;font-f= amily:Calibri,sans-serif;background-color:transparent;font-weight:700;font-= variant-numeric:normal;font-variant-east-asian:normal;font-variant-alternat= es:normal;vertical-align:baseline">SYMPTEMIST-entities:</span><span style= =3D"font-size:10pt;font-family:Calibri,sans-serif;background-color:transpar= ent;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant= -alternates:normal;vertical-align:baseline"> automatic detection of mention= s of symptoms.</span></p></li></ul><ul style=3D"margin-top:0px;margin-botto= m:0px"><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-fa= mily:Arial,sans-serif;color:rgb(0,0,0);background-color:transparent;font-va= riant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates= :normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p dir=3D= "ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"p= resentation"><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;b= ackground-color:transparent;font-weight:700;font-variant-numeric:normal;fon= t-variant-east-asian:normal;font-variant-alternates:normal;vertical-align:b= aseline">SYMPTEMIST-linking</span><span style=3D"font-size:10pt;font-family= :Calibri,sans-serif;background-color:transparent;font-variant-numeric:norma= l;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-al= ign:baseline">: finding mentions of symptoms and normalizing them to their = Snomed-CT concept identifiers.</span></p></li><li dir=3D"ltr" style=3D"list= -style-type:disc;font-size:10pt;font-family:Arial,sans-serif;color:rgb(0,0,= 0);background-color:transparent;font-variant-numeric:normal;font-variant-ea= st-asian:normal;font-variant-alternates:normal;vertical-align:baseline;whit= e-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;marg= in-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-siz= e:10pt;font-family:Calibri,sans-serif;background-color:transparent;font-wei= ght:700;font-variant-numeric:normal;font-variant-east-asian:normal;font-var= iant-alternates:normal;vertical-align:baseline">SYMPTEMIST-multilingual</sp= an><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;background-= color:transparent;font-variant-numeric:normal;font-variant-east-asian:norma= l;font-variant-alternates:normal;vertical-align:baseline">: automatic detec= tion of mentions of symptoms in versions of the corpus generated in English= , French, Italian, Portuguese, Romanian, Catalan, Dutch, Swedish and Czech.= </span></p></li></ul><p dir=3D"ltr" style=3D"line-height:1.44;margin-top:0p= t;margin-bottom:0pt"><span style=3D"font-size:10pt;font-family:Calibri,sans= -serif;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:n= ormal;font-variant-east-asian:normal;font-variant-alternates:normal;vertica= l-align:baseline"><br></span><span style=3D"font-size:10pt;font-family:Cali= bri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;vertical-align:baseline"><br></span><span style=3D"font-size:10pt;font-fam= ily:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-w= eight:700;font-variant-numeric:normal;font-variant-east-asian:normal;font-v= ariant-alternates:normal;vertical-align:baseline">Tentative schedule</span>= </p><ul style=3D"margin-top:0px;margin-bottom:0px"><li dir=3D"ltr" style=3D= "list-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;color:r= gb(0,0,0);background-color:transparent;font-variant-numeric:normal;font-var= iant-east-asian:normal;font-variant-alternates:normal;vertical-align:baseli= ne;white-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.= 38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"f= ont-size:10pt;background-color:transparent;font-variant-numeric:normal;font= -variant-east-asian:normal;font-variant-alternates:normal;vertical-align:ba= seline">Annotation Guidelines:</span><span style=3D"font-size:10pt;backgrou= nd-color:transparent;font-variant-numeric:normal;font-variant-east-asian:no= rmal;font-variant-alternates:normal;vertical-align:baseline"><span class=3D= "gmail-Apple-tab-span" style=3D"text-wrap: nowrap;"> </span></span><span st= yle=3D"font-size:10pt;background-color:transparent;font-variant-numeric:nor= mal;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-= align:baseline">August 8th 2023</span></p></li><li dir=3D"ltr" style=3D"lis= t-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0= ,0,0);background-color:transparent;font-variant-numeric:normal;font-variant= -east-asian:normal;font-variant-alternates:normal;vertical-align:baseline;w= hite-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;m= argin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-= size:10pt;background-color:transparent;font-variant-numeric:normal;font-var= iant-east-asian:normal;font-variant-alternates:normal;vertical-align:baseli= ne">Train Set Subtask 1 (NER): August 8th, 2023</span></p></li><li dir=3D"l= tr" style=3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-s= erif;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:nor= mal;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-= align:baseline;white-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"li= ne-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><spa= n style=3D"font-size:10pt;background-color:transparent;font-variant-numeric= :normal;font-variant-east-asian:normal;font-variant-alternates:normal;verti= cal-align:baseline">Train Set Subtask 2 (Linking): September 10th 2023</spa= n></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;fon= t-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;f= ont-variant-numeric:normal;font-variant-east-asian:normal;font-variant-alte= rnates:normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p = dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" rol= e=3D"presentation"><span style=3D"font-size:10pt;background-color:transpare= nt;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-= alternates:normal;vertical-align:baseline">Train Set Subtask 3 (Multilingua= l): September 10th 2023</span></p></li><li dir=3D"ltr" style=3D"list-style-= type:disc;font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);ba= ckground-color:transparent;font-variant-numeric:normal;font-variant-east-as= ian:normal;font-variant-alternates:normal;vertical-align:baseline;white-spa= ce:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-to= p:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:10p= t;background-color:transparent;font-variant-numeric:normal;font-variant-eas= t-asian:normal;font-variant-alternates:normal;vertical-align:baseline">Symp= TEMIST Test Set: September 30th 2023</span></p></li><li dir=3D"ltr" style= =3D"list-style-type:disc;font-size:10pt;font-family:Calibri,sans-serif;colo= r:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal;font-= variant-east-asian:normal;font-variant-alternates:normal;vertical-align:bas= eline;white-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height= :1.38;margin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style= =3D"font-size:10pt;background-color:transparent;font-variant-numeric:normal= ;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-ali= gn:baseline">Participants Test Predictions Deadline: October 5th 2023</span= ></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font= -family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;fo= nt-variant-numeric:normal;font-variant-east-asian:normal;font-variant-alter= nates:normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p d= ir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role= =3D"presentation"><span style=3D"font-size:10pt;background-color:transparen= t;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-a= lternates:normal;vertical-align:baseline">Participants Evaluation Results R= elease. October 10th 2023</span></p></li><li dir=3D"ltr" style=3D"list-styl= e-type:disc;font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);= background-color:transparent;font-variant-numeric:normal;font-variant-east-= asian:normal;font-variant-alternates:normal;vertical-align:baseline;white-s= pace:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-= top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:1= 0pt;background-color:transparent;font-variant-numeric:normal;font-variant-e= ast-asian:normal;font-variant-alternates:normal;vertical-align:baseline">Su= bmission of Participant Papers Deadline: October 22nd 2023</span></p></li><= li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-family:Cal= ibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-= numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma= l;vertical-align:baseline;white-space:pre;margin-left:11pt"><p dir=3D"ltr" = style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"present= ation"><span style=3D"font-size:10pt;background-color:transparent;font-vari= ant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:n= ormal;vertical-align:baseline">Notification of Acceptance Participant Paper= s: October 30 2023</span></p></li><li dir=3D"ltr" style=3D"list-style-type:= disc;font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);backgro= und-color:transparent;font-variant-numeric:normal;font-variant-east-asian:n= ormal;font-variant-alternates:normal;vertical-align:baseline;white-space:pr= e;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt= ;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:10pt;bac= kground-color:transparent;font-variant-numeric:normal;font-variant-east-asi= an:normal;font-variant-alternates:normal;vertical-align:baseline">Submissio= n of Camera-ready Participant Papers Deadline. November 1st 2023</span></p>= </li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;font-fami= ly:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-va= riant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates= :normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p dir=3D= "ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" role=3D"p= resentation"><span style=3D"font-size:10pt;background-color:transparent;fon= t-variant-numeric:normal;font-variant-east-asian:normal;font-variant-altern= ates:normal;vertical-align:baseline">BioCreative VIII workshop @ AMIA 2023:= November 11-15, 2023, In New Orleans, LA.</span></p></li></ul><p dir=3D"lt= r" style=3D"line-height:1.44;margin-top:0pt;margin-bottom:0pt"><span style= =3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);backgrou= nd-color:transparent;font-variant-numeric:normal;font-variant-east-asian:no= rmal;font-variant-alternates:normal;vertical-align:baseline"><br><br></span= ></p><p dir=3D"ltr" style=3D"line-height:1.44;margin-top:0pt;margin-bottom:= 0pt"><span style=3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb= (0,0,0);background-color:transparent;font-weight:700;font-variant-numeric:n= ormal;font-variant-east-asian:normal;font-variant-alternates:normal;vertica= l-align:baseline">BioCreative proceedings and AMIA workshop</span></p><p di= r=3D"ltr" style=3D"line-height:1.44;margin-top:0pt;margin-bottom:0pt"><span= style=3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);ba= ckground-color:transparent;font-weight:700;font-variant-numeric:normal;font= -variant-east-asian:normal;font-variant-alternates:normal;vertical-align:ba= seline"><br></span><span style=3D"font-size:10pt;font-family:Calibri,sans-s= erif;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:nor= mal;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-= align:baseline">Teams participating in SYMPTEMIST will be invited to contri= bute a systems description paper for the BioCreative=C2=A0 2023 Working Not= es proceedings and a flash presentation of their approach at the BioCreativ= e 2023 session. The BioCreative VIII workshop will run with AMIA 2023, Nove= mber 11-15, 2023, In New Orleans, LA. See: <a href=3D"https://amia.org/educ= ation-events/amia-2023-annual-symposium">https://amia.org/education-events/= amia-2023-annual-symposium</a></span></p><br><br><p dir=3D"ltr" style=3D"li= ne-height:1.44;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-size:1= 0pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transp= arent;font-weight:700;font-variant-numeric:normal;font-variant-east-asian:n= ormal;font-variant-alternates:normal;vertical-align:baseline">Workshop Proc= eedings and Special Issue</span><span style=3D"font-size:10pt;font-family:C= alibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-varian= t-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:nor= mal;vertical-align:baseline">:</span></p><br><p dir=3D"ltr" style=3D"line-h= eight:1.44;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-size:10pt;= font-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparen= t;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-a= lternates:normal;vertical-align:baseline">The BioCreative VIII Proceedings = will host all the submissions from participating teams, and it will be free= ly available by the time of the workshop. In addition, we are happy to anno= unce that the journal Database will host the BioCreative VIII special issue= for work that has passed their peer-review process. Invitation to submit w= ill be sent after the workshop.=C2=A0</span></p><p dir=3D"ltr" style=3D"lin= e-height:1.44;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-size:10= pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transpa= rent;font-variant-numeric:normal;font-variant-east-asian:normal;font-varian= t-alternates:normal;vertical-align:baseline"><br><br></span></p><p dir=3D"l= tr" style=3D"line-height:1.44;margin-top:0pt;margin-bottom:0pt"><span style= =3D"font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);backgrou= nd-color:transparent;font-weight:700;font-variant-numeric:normal;font-varia= nt-east-asian:normal;font-variant-alternates:normal;vertical-align:baseline= ">All BioCreative VIII tracks</span></p><p dir=3D"ltr" style=3D"line-height= :1.44;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-size:10pt;font-= family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;fon= t-variant-numeric:normal;font-variant-east-asian:normal;font-variant-altern= ates:normal;vertical-align:baseline">Track 1: BioRED (Biomedical Relation E= xtraction Dataset)</span></p><p dir=3D"ltr" style=3D"line-height:1.44;margi= n-top:0pt;margin-bottom:0pt"><span style=3D"font-size:10pt;font-family:Cali= bri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;vertical-align:baseline">*Track 2: SYMPTEMIST (Symptom TExt Mining Shared = Task)</span></p><p dir=3D"ltr" style=3D"line-height:1.44;margin-top:0pt;mar= gin-bottom:0pt"><span style=3D"font-size:10pt;font-family:Calibri,sans-seri= f;color:rgb(0,0,0);background-color:transparent;font-variant-numeric:normal= ;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-ali= gn:baseline">Track 3: Genetic Phenotype Extraction and Normalization from D= ysmorphology Physical Examination Entries</span></p><p dir=3D"ltr" style=3D= "line-height:1.44;margin-top:0pt;margin-bottom:0pt"><span style=3D"font-siz= e:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:tra= nsparent;font-variant-numeric:normal;font-variant-east-asian:normal;font-va= riant-alternates:normal;vertical-align:baseline">Track 4: Clinical Annotati= on Tool Track</span></p><br><p dir=3D"ltr" style=3D"line-height:1.44;margin= -top:0pt;margin-bottom:0pt"><span style=3D"font-size:10pt;font-family:Calib= ri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-variant-nu= meric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;= vertical-align:baseline"><br></span><span style=3D"font-size:10pt;font-fami= ly:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;font-we= ight:700;font-variant-numeric:normal;font-variant-east-asian:normal;font-va= riant-alternates:normal;vertical-align:baseline">Main Organizers</span></p>= <ul style=3D"margin-top:0px;margin-bottom:0px"><li dir=3D"ltr" style=3D"lis= t-style-type:disc;font-size:10pt;font-family:Arial,sans-serif;color:rgb(0,0= ,0);background-color:transparent;font-variant-numeric:normal;font-variant-e= ast-asian:normal;font-variant-alternates:normal;vertical-align:baseline;whi= te-space:pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;mar= gin-top:0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-si= ze:10pt;font-family:Calibri,sans-serif;background-color:transparent;font-va= riant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates= :normal;vertical-align:baseline">Martin Krallinger, Barcelona Supercomputin= g Center, Spain</span></p></li><li dir=3D"ltr" style=3D"list-style-type:dis= c;font-size:10pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background-c= olor:transparent;font-variant-numeric:normal;font-variant-east-asian:normal= ;font-variant-alternates:normal;vertical-align:baseline;white-space:pre;mar= gin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;marg= in-bottom:0pt" role=3D"presentation"><span style=3D"font-size:10pt;font-fam= ily:Calibri,sans-serif;background-color:transparent;font-variant-numeric:no= rmal;font-variant-east-asian:normal;font-variant-alternates:normal;vertical= -align:baseline">Eul=C3=A0lia Farr=C3=A9-Maduell, Barcelona Supercomputing = Center, Spain</span></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;= font-size:10pt;font-family:Arial,sans-serif;color:rgb(0,0,0);background-col= or:transparent;font-variant-numeric:normal;font-variant-east-asian:normal;f= ont-variant-alternates:normal;vertical-align:baseline;white-space:pre;margi= n-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin= -bottom:0pt" role=3D"presentation"><span style=3D"font-size:10pt;font-famil= y:Calibri,sans-serif;background-color:transparent;font-variant-numeric:norm= al;font-variant-east-asian:normal;font-variant-alternates:normal;vertical-a= lign:baseline">Luis Gasc=C3=B3, Barcelona Supercomputing Center, Spain</spa= n></p></li><li dir=3D"ltr" style=3D"list-style-type:disc;font-size:10pt;fon= t-family:Calibri,sans-serif;color:rgb(0,0,0);background-color:transparent;f= ont-variant-numeric:normal;font-variant-east-asian:normal;font-variant-alte= rnates:normal;vertical-align:baseline;white-space:pre;margin-left:11pt"><p = dir=3D"ltr" style=3D"line-height:1.38;margin-top:0pt;margin-bottom:0pt" rol= e=3D"presentation"><span style=3D"font-size:10pt;background-color:transpare= nt;font-variant-numeric:normal;font-variant-east-asian:normal;font-variant-= alternates:normal;vertical-align:baseline">Salvador Lima, Barcelona Superco= mputing Center, Spain</span></p></li><li dir=3D"ltr" style=3D"list-style-ty= pe:disc;font-size:10pt;font-family:Calibri,sans-serif;color:rgb(0,0,0);back= ground-color:transparent;font-variant-numeric:normal;font-variant-east-asia= n:normal;font-variant-alternates:normal;vertical-align:baseline;white-space= :pre;margin-left:11pt"><p dir=3D"ltr" style=3D"line-height:1.38;margin-top:= 0pt;margin-bottom:0pt" role=3D"presentation"><span style=3D"font-size:10pt;= background-color:transparent;font-variant-numeric:normal;font-variant-east-= asian:normal;font-variant-alternates:normal;vertical-align:baseline">Jan Ro= driguez, Barcelona Supercomputing Center, Spain</span></p></li></ul><br><br= ></span><div><br></div><div dir=3D"ltr" class=3D"gmail_signature" data-smar= tmail=3D"gmail_signature"><div dir=3D"ltr"><div dir=3D"ltr"><div dir=3D"ltr= "><div dir=3D"ltr"><div dir=3D"ltr"><div dir=3D"ltr"><div dir=3D"ltr"><div = dir=3D"ltr"><div>=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D<br>Martin Kral= linger, Dr.<br><span style=3D"font-family:arial,helvetica,sans-serif">Head = of NLP for Biomedical Information Analysis Unit<br></span><span style=3D"fo= nt-family:arial,helvetica,sans-serif">Barcelona Supercomputing Center (BSC-= CNS)</span></div><div><span><font face=3D"arial, helvetica, sans-serif"><a = href=3D"https://www.linkedin.com/in/martin-krallinger-85495920/" target=3D"= _blank">https://www.linkedin.com/in/martin-krallinger-85495920/</a><br></fo= nt></span>=C2=A0<span>=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D</span><b= r></div></div></div></div></div></div></div></div></div></div></div> --000000000000e22a4806033433d8-- --===============6986709136075456075== Content-Type: text/plain; charset="us-ascii" MIME-Version: 1.0 Content-Transfer-Encoding: 7bit Content-Disposition: inline _______________________________________________ Corpora mailing list -- [email protected] https://list.elra.info/mailman3/postorius/lists/corpora.list.elra.info/ To unsubscribe send an email to [email protected] --===============6986709136075456075==--